マクロファージコロニー刺激因子1受容体治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0970
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:255
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Macrophage Colony Stimulating Factor 1 Receptor – Pipeline Review, H1 2020
Summary

According to the recently published report ‘Macrophage Colony Stimulating Factor 1 Receptor – Pipeline Review, H1 2020′; Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 49 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes.

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.

The report ‘Macrophage Colony Stimulating Factor 1 Receptor – Pipeline Review, H1 2020′ outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 12, 5, 1, 12 and 8 respectively. Similarly, the universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 2, 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Musculoskeletal Disorders, Genetic Disorders, Gastrointestinal and Respiratory which include indications Solid Tumor, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Bile Duct Cancer (Cholangiocarcinoma), Epithelial Ovarian Cancer, Pancreatic Cancer, Tenosynovial Giant Cell Tumor, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Peritoneal Cancer, Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bladder Cancer, Breast Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Soft Tissue Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Chronic Myelomonocytic Leukemia (CMML), Endometrial Cancer, Follicular Thyroid Cancer, Graft Versus Host Disease (GVHD), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Medullary Thyroid Cancer, Metastatic Pancreatic Cancer, Neuroinflammation, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Pigmented Villonodular Synovitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Salivary Gland Cancer, Thyroid Cancer, Acral Lentiginous Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Asthma, Auto Inflammatory Disease, Bone Metastasis, Brenner Tumor, Charcot-Marie-Tooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Ependymoma, Esophageal Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Gliosarcoma, High-Grade Glioma, Hormone Sensitive Breast Cancer, Inflammation, Lentigo Maligna Melanoma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Liposarcoma, Lung Adenocarcinoma, Malignant Mesothelioma, Malignant Neoplasms, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Osteolysis, Osteoporosis, Osteosarcoma, Pain, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Pheochromocytoma, Primary Progressive Multiple Sclerosis (PPMS), ), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Small-Cell Lung Cancer, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Tauopathies, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transformed Mycosis Fungoides, Uveal Melanoma and Von Hippel-Lindau Syndrome.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
Introduction
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Overview
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Therapeutics Development
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Therapeutics Assessment
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Companies Involved in Therapeutics Development
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Drug Profiles
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Dormant Products
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Discontinued Products
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Companies, H1 2020 (Contd..11), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AB Science SA, H1 2020
Pipeline by Abbisko Therapeutics Co Ltd, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Apollomics Inc, H1 2020
Pipeline by BCI Pharma SA, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by CrystalGenomics Inc, H1 2020
Pipeline by CTI BioPharma Corp, H1 2020
Pipeline by Deciphera Pharmaceuticals Inc, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Elixiron Immunotherapeutics Inc, H1 2020
Pipeline by Elsalys Biotech SA, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Flavocure Biotech LLC, H1 2020
Pipeline by GigaGen Inc, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
Pipeline by Hutchison MediPharma Ltd, H1 2020
Pipeline by ImmunoForge Co Ltd, H1 2020
Pipeline by Jiangsu Suzhong Pharmaceutical Group Co Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by NMS Group SpA, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Oncodesign SA, H1 2020
Pipeline by Oncology Venture A/S, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Plexxikon Inc, H1 2020
Pipeline by Provention Bio Inc, H1 2020
Pipeline by Samjin Pharm Co Ltd, H1 2020
Pipeline by Shattuck Labs Inc, H1 2020
Pipeline by SignalChem Lifesciences Corp, H1 2020
Pipeline by Suntec Medical (Taiwan) Inc, H1 2020
Pipeline by Syndax Pharmaceuticals Inc, H1 2020
Pipeline by The National Institute for Biotechnology in the Negev Ltd, H1 2020
Pipeline by Transcenta Holding Ltd, H1 2020
Pipeline by Turning Point Therapeutics Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Dormant Products, H1 2020 (Contd..4), H1 2020
Dormant Products, H1 2020 (Contd..5), H1 2020
Dormant Products, H1 2020 (Contd..6), H1 2020
Dormant Products, H1 2020 (Contd..7), H1 2020
Dormant Products, H1 2020 (Contd..8), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020 (Contd..3), H1 2020

【掲載企業】

AB Science SA
Abbisko Therapeutics Co Ltd
Amgen Inc
Apollomics Inc
BCI Pharma SA
Bristol-Myers Squibb Co
CrystalGenomics Inc
CTI BioPharma Corp
Deciphera Pharmaceuticals Inc
Eli Lilly and Co
Elixiron Immunotherapeutics Inc
Elsalys Biotech SA
F. Hoffmann-La Roche Ltd
Flavocure Biotech LLC
GigaGen Inc
GlaxoSmithKline Plc
Hanmi Pharmaceuticals Co Ltd
Hutchison MediPharma Ltd
ImmunoForge Co Ltd
Jiangsu Suzhong Pharmaceutical Group Co Ltd
Merck & Co Inc
NMS Group SpA
Novartis AG
Oncodesign SA
Oncology Venture A/S
Pfizer Inc
Plexxikon Inc
Provention Bio Inc
Samjin Pharm Co Ltd
Shattuck Labs Inc
SignalChem Lifesciences Corp
Suntec Medical (Taiwan) Inc
Syndax Pharmaceuticals Inc
The National Institute for Biotechnology in the Negev Ltd
Transcenta Holding Ltd
Turning Point Therapeutics Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[マクロファージコロニー刺激因子1受容体治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆